|
|
 |
|
Viewing report
|
|
|
|
Wockhardt Generics Company Intelligence Report
Espicom Business Intelligence Ltd, Jan 2011, Pages: 14
The Indian company, Wockhardt Limited, was founded nearly four decades ago, and today claims its place amongst the country's top research and technology oriented pharmaceutical companies.
The company has subsidiaries in the United States, the United Kingdom and Brazil, and majority-owned companies in South Africa and Mexico. The company also has marketing offices in Africa, Russia, Central Asia and South East Asia.
In October 2007, Wockhardt acquired the US firm, Morton Grove Pharmaceuticals. The acquisition more than doubled Wockhardt’s US portfolio, adding 31 products to the firm’s existing 23 marketed in the country.
In 2003, the company launched Wosulin, a recombinant insulin product. In doing so, Wockhardt became the fourth company, and first Asian manufacturer, to be able to offer the product. Wockhardt has identified biopharmaceuticals as a major developing market area, and is making plans to sell generic biopharmaceuticals in the US and EU once regulatory pathways have been established.
Wockhardt's consolidated sales for 2008 reached Rs36,281 million (US$837.7 million), representing an increase of 43.7% over the prior year. However, the firm incurred a loss of Rs1,389 million (US$32.1 million). The firm had a difficult year in 2008, which has led to it divesting a number of businesses, including its German business, Esparma.
Wockhardt's consolidated sales and services for the 15 month period ended 31st March 2010 reached Rs45,059.0 million (US$941.28 million), with total revenue worth Rs45,309.5 million (US$946.5 million). However, the firm reported a net loss of Rs10,023.0 million (US$209.4 million).
Executive Summary
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
|
|
|
|
